The spread of drug-resistant bacteria is a global health concern and could once again become a leading cause of mortality. The World Health Organization has flagged carbapenem-resistant Acinetobacter ...
Spanish VC firm Asabys Partners has closed its second fund at €180 million (US$201.3 million), to be invested in seed to ...
China’s National Medical Products Administration (NMPA) has accepted NDAs for Innovent Biologics Inc.’s IL-23p19 antibody ...
In some ways, remote patient monitoring (RPM) came of age during the COVID-19 pandemic, but payers still worry about the ...
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
Endometrial cancer (EC) accounts for 20% to 30% of most malignant tumors of the female reproductive system, making it one of ...
The U.S. FDA’s approval of yet another indication for Dupixent (dupilumab), partnered between Regeneron Pharmaceuticals Inc. and Sanofi SA, could mean another $6.4 billion-plus in sales by the end of ...
Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the ...
A collaborating team of researchers from the U.K.’s University College London and the Incliva Biomedical Research Institute in Valencia, Spain, filed for protection of a machine learning model called ...
In August 2024, BioWorld tracked 92 clinical trial updates, a decrease from the 121 reported in July. The month included nine successful phase III trials, three with mixed outcomes and three failures.
Korean med-tech firm Innosys Co. Ltd. recently launched two new injectable spine bone graft substitute products – Velofuse Gel and Velofuse Putty – and announced a name change to CG Medtech Co. Ltd., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback